Related Experiment Video
Updated: Oct 10, 2026
Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
M30 expression demonstrates apoptotic cells, correlates with in situ end-labeling, and is associated with Ki-67
1Department of Pathology, Royal Hospital Haslar, Gosport, Hampshire, United Kingdom.
Context:
The monoclonal antibody M30 recognizes a neoepitope of cytokeratin 18 produced during apoptosis. It is reactive in formalin-fixed, paraffin-embedded tissue and has great potential in the study of apoptosis in clinical and experimental material.
Objectives:
To compare the results of M30 immunoexpression with a more established technique of demonstrating apoptosis in tissue sections, in situ end-labeling. A secondary objective was to compare the results with immunoexpression of the proliferation-associated antigen Ki-67.
Design:
Retrospective analysis of adenomas and adenocarcinomas of the large intestine.
Interventions:
Immunohistochemistry for M30 and Ki-67, and in situ end-labeling. Formalin-fixed, paraffin-embedded tissue was used.
Main Outcome Measures:
The number of cells positive for M30, Ki-67, and in situ end-labeling, expressed as a proportion of the total number of cells counted.
Results:
A strong positive correlation was found between in situ end-labeling and expression of M30, although the counts were widely scattered around the regression line. Counts of Ki-67 were strongly correlated with both M30 expression and in situ end-labeling. Immunoexpression of M30 was generally easier to interpret than in situ end-labeling, and the procedures for M30 immunohistochemistry were technically less exacting.
Conclusion:
These findings support the application of M30 immunoreactivity in the study of apoptosis.
Insights
The M30 antibody reliably detects apoptosis in tissues, correlating well with in situ end-labeling and Ki-67 expression. This method is easier to interpret and technically simpler for studying apoptosis.
Area of Science:
- Oncology
- Cell Biology
- Histopathology
Background:
- Monoclonal antibody M30 targets a neoepitope of cytokeratin 18 generated during apoptosis.
- M30 is reactive in formalin-fixed, paraffin-embedded tissues, showing potential for apoptosis studies in clinical and experimental settings.
Purpose of the Study:
- To compare M30 immunoexpression with in situ end-labeling for apoptosis detection.
- To correlate M30 and in situ end-labeling results with Ki-67 immunoexpression, a marker of proliferation.
Main Methods:
- Retrospective analysis of large intestine adenomas and adenocarcinomas.
- Immunohistochemistry for M30 and Ki-67, alongside in situ end-labeling on formalin-fixed, paraffin-embedded tissues.
Main Results:
- A strong positive correlation was observed between M30 expression and in situ end-labeling.
- Ki-67 expression strongly correlated with both M30 and in situ end-labeling.
- M30 immunoexpression offered easier interpretation and was technically less demanding than in situ end-labeling.
Conclusions:
- M30 immunoreactivity is a valuable tool for studying apoptosis.
- The findings support the use of M30 in research and clinical settings for apoptosis assessment.
